ADP受体抑制剂在急性冠状动脉综合征应用中的研究进展

抗血小板聚集药物的使用是治疗急性冠状动脉综合征的关键环节,作为ADP受体抑制剂之一,氯吡格雷是临床广泛应用的抗血小板聚集药物。随着一系列关于抗血小板循证医学实验结果的披露,其他新型的ADP受体抑制剂(如替卡格雷、普拉格雷等)在抗血小板方面显示出与氯吡格雷不同的特点。

Research Progress of ADP Receptor Inhibitors in Acute Coronary Syndrome

The use of anti-platelet aggregation drug plays an important role in the treatment of acute coronary syndrome(ACS).As a key drug in ACS,one of the inhibitors of ADP receptor,clopidogrel is widely used for anti-platelet aggregation.Other new ADP receptor inhibitors such as ticagrelor and prasugrel show different characteristics compared with clopidogrel,as documented by a series of evidence-based antiplatelet experiment results.